Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 11
1974 48
1975 40
1976 47
1977 48
1978 63
1979 91
1980 98
1981 125
1982 106
1983 106
1984 150
1985 149
1986 149
1987 145
1988 165
1989 327
1990 344
1991 214
1992 274
1993 300
1994 331
1995 325
1996 338
1997 348
1998 295
1999 394
2000 361
2001 388
2002 323
2003 434
2004 565
2005 803
2006 704
2007 642
2008 515
2009 523
2010 478
2011 603
2012 592
2013 569
2014 510
2015 472
2016 480
2017 488
2018 441
2019 450
2020 586
2021 520
2022 392
2023 367
2024 390
2025 342

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,184 results

Results by year

Filters applied: . Clear all
Page 1
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Brown J, et al. Gynecol Oncol. 2024 Nov;190:283-290. doi: 10.1016/j.ygyno.2024.09.002. Epub 2024 Sep 12. Gynecol Oncol. 2024. PMID: 39265466 Free PMC article. Clinical Trial.
Introduction.
[No authors listed] [No authors listed] Gynecol Oncol. 2025 Mar;194:A1. doi: 10.1016/j.ygyno.2025.03.025. Gynecol Oncol. 2025. PMID: 40221175 No abstract available.
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Powell MA, et al. Gynecol Oncol. 2025 Jan;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. Epub 2024 Nov 12. Gynecol Oncol. 2025. PMID: 39531903 Free article. Clinical Trial.
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Regináčová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaříková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Makker V, et al. Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3. Gynecol Oncol. 2024. PMID: 38834399 Free article. Clinical Trial.
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W Jr, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Clements A, et al. Gynecol Oncol. 2025 Feb;193:119-129. doi: 10.1016/j.ygyno.2025.01.006. Epub 2025 Jan 23. Gynecol Oncol. 2025. PMID: 39854806 Clinical Trial.
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. Gynecol Oncol. 2024. PMID: 39461270
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Matulonis UA, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, Berek JS, Haslund CA, Marmé F, González-Martín A, Bécourt S, Tinker AV, Ledermann JA, Benigno B, Lindahl G, Colombo N, Malinowska IA, Liu W, Bains M, Monk BJ, Mirza MR. Matulonis UA, et al. Gynecol Oncol. 2025 Apr;195:192-199. doi: 10.1016/j.ygyno.2025.03.018. Epub 2025 Mar 25. Gynecol Oncol. 2025. PMID: 40139026 Clinical Trial.
16,184 results
You have reached the last available page of results. Please see the User Guide for more information.